Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | completed | Phase 1 | 6 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00354926 |
| Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma |
| completed |
| Phase 1 |
| 67 |
| Applied Molecular EvolutionINDUSTRY |
| 1 |
| Jan 7, 2016 |
| clinicaltrials |
| NCT00141297 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | completed | Phase 1 | 74 | PfizerINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00588328 | The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00002818 | High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | completed | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT00717925 | Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 | 13 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Dec 9, 2015 | clinicaltrials |
| NCT00001575 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | completed | Phase 1 / Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01397799 | Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 24 | Kinex Pharmaceuticals Inc.INDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00039117 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00693433 | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01276717 | Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma | completed | Phase 1 | 20 | University of RochesterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00303290 | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01421173 | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | completed | Phase 1 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00561756 | Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00893464 | A Study of IXAZOMIB in Adult Patients With Lymphoma | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 11, 2015 | clinicaltrials |
| NCT01902160 | Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01314599 | Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | completed | Phase 1 | 45 | PharmaMarINDUSTRY | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01588548 | Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | completed | Phase 1 | 43 | AstraZenecaINDUSTRY | 2 | Nov 4, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT01632852 | A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission | completed | Phase 1 | 30 | CSL LimitedINDUSTRY | 2 | Oct 9, 2015 | clinicaltrials |
| NCT01149408 | Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients | completed | Phase 1 | 3 | University of UtahOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01039155 | Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 31 | BiogenINDUSTRY | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00127140 | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 28, 2015 | clinicaltrials |
| NCT00435084 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | completed | Phase 1 / Phase 2 | 10 | Valerio TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00916630 | Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01317927 | A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies | completed | Phase 1 | 27 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00364676 | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 1 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Sep 22, 2015 | clinicaltrials |
| NCT00479232 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | completed | Phase 1 | 71 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2015 | clinicaltrials |
| NCT01016600 | Azacitidine and Lenalidomide for Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 31 | Washington University School of MedicineOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT01127009 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01435863 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 | 17 | Solasia Pharma K.K.INDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00045513 | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00101153 | Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Jan 21, 2016source: clinicaltrials